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Clinical practice guideline (guideline) development methods in India have come under 
increased scrutiny in the recent decade with a growing interest on the use of evidence 
in guideline development.  
Methods: 
Guidelines on the four leading causes of disability adjusted life years in India 
(ischaemic heart disease, lower respiratory infections, chronic obstructive pulmonary 
diseases, tuberculosis), published on or after 2010 was searched in electronic 
databases and by other methods and their quality appraised by using the AGREE-II 
appraisal tool. In-depth, semi-structured interviews were conducted with 15 individuals 
involved with the development of the included guidelines and the transcripts were 
analysed using the framework approach.  
Results: 
  
We included eleven guidelines. The median AGREE II domain scores was highest for 
'scope and purpose' (81%) and 'clarity of presentation' (76%), and lowest for 'rigour of 
development' (31%) and ‘editorial independence’ (33%). 
Four main themes emerged from the interviews: (1) Guideline development in India is 
undergoing transition towards adoption of systematic, transparent and evidence based 
approaches but several barriers in the form of attitudes towards use of evidence, lack 
of methodological capacity ,inadequate governance structure and funding exist ; (2) 
Guideline development is an academic activity restricted to elite institutions and this 
affects panel composition, the consultative process and implementation of guidelines  
(3) Mixed views on patient involvement in guideline development; (4)Taboo & Poor 
understanding of  issues surrounding conflict of interests 
Conclusion: 
A multitude of efforts is needed by issuing agencies and the government to ensure 
development of guidelines in transparent, evidence based and a systematic manner 
with high quality in India.  
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Clinical practice guidelines(guidelines) aim to improve quality of care and health 
system performance by providing a framework against which clinical practice can be 
measured(1) . Apart from clinical decision making, they also enable healthcare 
managers and policy makers to make decisions regarding planning, commissioning, 
and purchasing of health care services and set priorities (2).  
Several factors which plague health systems universally are responsible for the 
increased importance being accorded to guidelines. The factors include, but are not 
limited to increased demand on health care services, rising health care costs, 
increasing medical practice litigation, use of private insurance for healthcare financing 
and concerns about overuse of health care interventions (2, 3). However, the quality of 
guidelines has been found to be modest to low. In many cases, the methods used fell 
short of even basic standards and were not based on research evidence (4-6). Poor 
quality guidelines are detrimental for making informed decisions as policy makers, 
funders and healthcare professionals in most cases do not have the necessary 
knowledge and skills to be able to assess its quality and determine its utility. These 
issues are international but very little is known about the quality of guidelines and its 
development in India. 
In India, there is a growing realisation that healthcare outcomes can be achieved 
optimally only if increased access to healthcare services is matched with improved 
quality of care(7-9). The National Health Policy 2017, has for the first time recognised 
the need to ensure adherence to standard treatment guidelines in both the public and 
the private sector(10).. The vast private sector, largely unregulated is known to use 
non-evidence based unnecessary interventions including expensive diagnostic tests 
and surgeries to maximise their profits (11-13) has a huge interest in the 
recommendations being made in guidelines. Under the federal set up of the Indian 
Constitution, health is a “State Subject” wherein the Government of India (GOI) can 
only enact model guidelines, and it is up to the state governments to accept, adapt, or 
discard them or develop their own guidelines. As such a plethora of government 
organisations and agencies, at the national and state level, as well as professional 
associations and societies develop guidelines. In 2015 the  Indian Council of Medical 
Research(ICMR) identified evidence informed health policy as its top priority (14). 
Since 2015, NICE International, UK is also providing technical assistance to the GOI 
  
to help develop evidence-based national standard treatment guidelines (15).  Despite 
the importance of guidelines in India and growing interest in the use of evidence in 
them, almost nothing is known about the development and quality of Indian guidelines, 
and how evidence is used in the guideline development process. In this paper, we aim 
to fill this knowledge gap with respect to Indian guidelines for four conditions with 




The study consisted of a cross-sectional appraisal of quality of Indian guidelines for 
four conditions with highest disease burden in India followed by a qualitative 
component which involved in-depth interviews with those who developed these 
guidelines  
Eligibility Criteria for inclusion of guidelines 
In the absence of any formal definition of guideline in India, we defined a guideline as 
“any formal statement containing recommendations with regards to any aspect of 
clinical practice (preventive/ diagnostic/therapeutic) and intended for use by health 
care professionals, recipients or any other stakeholder, irrespective of the label 
accorded to it by the issuing authority.” A document, which focused primarily on 
providing recommendations on operational, technical or regulatory aspects of 
healthcare, was not considered as a guideline in this study.  
We included guidelines from India published after January 01, 2010 on four conditions 
with the highest disability adjusted life years(DALY) in India - ischaemic heart 
disease(IHD), chronic obstructive pulmonary disease (COPD), lower respiratory 
infections(LRI), and tuberculosis(TB) (16) were eligible for inclusion in the study. 
Diseases associated with these causes were identified from the online database of the 
International Classification of Diseases-Tenth Revision (17). 
We excluded guidelines which:  
1. were developed with an international or continental scope (example South 
Asian/Asian) even if they were endorsed by an Indian issuing authority.  
  
2. were on multiple conditions, even if they had a component of one of the four 
causes of our interest.  
3. were on Ayurveda, Siddha, homeopathy, Yoga or any other alternative or 
complimentary medicine. 
Search methods for Identification of guidelines 
 
We searched Pubmed/MEDLINE, CINAHL, Global Health (EBSCO Host) on 8th May 
2016. Detailed search strategies are provided in Appendix 1. We also searched 
websites of relevant agencies and organisations manually between 8th May and 15th 
May 2016( Appendix 2). We also contacted seven subject experts and searched 
references of included guidelines. 
Selection of Guidelines 
We screened titles and/or abstracts of all records retrieved to identify potentially eligible 
articles and excluded duplicates. Full-texts were obtained in the final phase to make 
decisions on eligibility. 
Appraisal of quality of guidelines 
We appraised the quality of guidelines by using the AGREE II instrument (Appraisal of 
Guidelines Research and Evaluation) (18) .The AGREE II tool consists of 23 items in 
6 domains (Scope and purpose, Stakeholder involvement, Rigour of development. 
Clarity of Presentation, Applicability, Editorial Independence) and two overall 
assessment domains. The 23 items are each rated on a score from 1(strongly 
disagree) to 7(strongly agree).  
Three appraisers independently appraised the guidelines. One author (SB) acted as 
the first appraiser for all included guidelines whereas other authors acted as second or 
third appraisers. As a measure of quality control, all appraisers mandatorily attended 
the Systematic Reviews: Policy or Practice module in Liverpool School of Tropical 
Medicine (which has a hands on component on use of AGREE II), and had completed 
the AGREE II Online Training Module. The AGREE II online training module, includes 
a practicum which allows comparison of acquired rating skills for a given guideline with 
standard ratings given by international experts (18). The appraisal of the guidelines 
was done vide an online data management system available in the AGREE TRUST 
website (http://www.agreetrust.org/ ) which blinds the appraisers from each other and 
  
automatically calculates the standardised quality scores (18) for each domain. The 
overall assessment score is not an aggregate of individual domain scores but an 
independent domain in itself (18). 
Qualitative component of study 
 
Any persons involved in the development of guidelines, whose quality was appraised 
in the first part of the study and whose e-mail address could be acquired publicly 
constituted the sampling frame for the study, were approached through e-mail. We 
conducted in-depth semi structured interviews with all persons who expressed 
willingness to participate, and gave consent for the same. Interviews were conducted 
by a single author (SB) through Skype or telephone or in a face to face manner in 
English using an interview topic guide. The topic guide consisted of a few mapping 
questions, broad open ended questions as well as specific probes. An iterative 
approach was adopted and additional issues were explored as themes emerged from 
interviews with previous participants. No fixed order was followed for asking questions 
and the natural flow of conversation was allowed.  If any interview was interrupted due 
to network connectivity issues, it was resumed from the point it got interrupted.  
For Skype or telephonic interviews participants were free to choose a setting they 
preferred and no data was collected on it.  At the researchers end no other person was 
present. For face-to-face interviews were conducted at the office of the participants 
which was a secure private room with only the researcher and the participant. 
All interviews were transcribed and the transcripts were cross checked with the 
recording twice to ensure the accuracy. Transcripts were not returned to participants. 
The framework analyses approach  for analysing the data as it is most suitable and 
flexible tool for developing themes from semi-structured interviews , particularly for 
applied health research (19) . Initially coding was done manually but once the final 
thematic framework was obtained, data management and analyses was done in the 
software NVIVO 11 (Version: NVivo Pro) 
Ethics  
The study had been reviewed and approved by the LSTM Ethics committee. Informed 




A total of 7439 records were retrieved and after initial screening and removal of 
duplicates, we identified 20 records for full text retrieval. Full text of two records was 
not available in public domain. The final version of one of these, which was due public 
release on August 2016, was made available to the research team while the other 
guideline was still under development. We finally included 11 guidelines  (20-30). The 
PRISMA flowchart (31) is shown in Figure 1 . 
Description of Included Guidelines  
Key characteristics of the eleven included guidelines is summarised in Table 1. We 
found the following guidelines - four on IHD, one on COPD, one on LRI, and five on 
TB. 
Findings on AGREE II Guideline Quality scores  
The AGREE II scores for the included guidelines is shown in Table 2. The summary 
scores across different domains is also demonstrated graphically in Figure 2 .The 
median domain score was high for the domains of “Scope and Purpose” [81% (57% -
98%)] and clarity of presentation [76% (59% - 92%)] while it was poor for domains of 
“Stakeholder involvement” [48% (26 % - 78%)], “Applicability” [40%(22% - 75%)] and 
“Editorial independence” [33% (11% - 92%.)]. This domain score for the “Rigour of 
Development” had the lowest median scores (31%)among all the domains but scores 
between guidelines varied. Six of the eleven guidelines has scores less than 31% with 
the lowest being 15% for the domain of “Rigour of Development”. 
The overall assessment scores ranged from 22% to 94% with a median score of 67%. 
Only four guidelines had overall scores more than 70%. In the Overall 
Recommendation domain only a single guideline was recommended ‘Yes’ by all three 
appraisers. One guideline was recommended as ‘No’ by all three appraisers.  Others 
received intermediate ratings. 
Description of participants in qualitative component study.  
In total, 15 participants with varying levels of seniority, background, prior involvement 
in guideline development (single or multiple) and prior experience in conducting 
  
systematic review were interviewed. Participant characteristics are summarised in 
Table 3.   
Themes  
The themes, and sub-themes which emerged has been summarily illustrated in Table 
4.  and described in subsequent sections. Participant are presented as numerical 
codes (P1, P2, P3 etc). PX indicates the non-disclosure of numerical code to prevent 
deductive disclosure.  
Theme 1: Guideline development in India is undergoing transition  
This theme outlines the transition in attitudes and practices towards use of evidence in 
guideline development and how it is influenced by contextual factors, governance, 
funding and availability of methodological capacity.  
Transition in attitudes and practices towards use of evidence 
Majority of the participants mentioned that there has been a change in attitudes and 
practices towards adoption of transparent, evidence based approaches for guideline 
development since the last few years, although they acknowledged that there was need 
to do more:  
“Traditionally the guideline used to be, what I would call like a sermon given in 
Sunday morning church - it used to be like some kind of preaching. Now more 
guidelines are evidence based…”- P9 
However, some senior clinicians who have been involved in development of multiple 
guidelines mentioned that:  
“.. people say we use evidence but it is not in a structured transparent way…they 
do not give you any section which gives information about how they came up 
with recommendations, conflicts of interests and stuff.”- P6   
Few participants also expressed their preference towards indigenous Indian data over 
systematic reviews :  
  
"... people are resorting to the evidence that is there in the Cochrane Library…. 
But then some of the evidence is not from our own country ...that is a problem 
in formulating guidelines” - P2 
Contextual factors are driving transition  
Participants recognised that the transition in guideline development in India was driven 
by need for greater transparency and accountability in health care decision making, 
increased health literacy and push from other health system actors and utility of 
evidence in convincing policy makers.  
“…people want more answerability, they want to know why you are doing this and 
also the widespread availability of the so-called free available literature on the 
internet … That has brought out a necessity in the medical professionals to be 
more responsive to the needs of patient, and also justify their actions...”- P14 
"… he got NICE International to come and teach how to do and develop 
guidelines in Maternal and Child Health. NICE used to go to various states and 
it picked up the initiative ..."- P6 
 “… policy makers are not necessarily medical professionals…They may have 
their own whims and fancies and they will tell you, you do like this... There it helps 
to say that this does not have the evidence backing and that evidence is to the 
contrary.”- PX 
 
Better governance is needed to facilitate transition  
Many participants acknowledged that guideline development was usually unplanned 
and ad hoc in nature and they described four types of co-ordination issues: between 
different government agencies, between government and professional societies, 
between different professional societies and between those generating evidence and 
those formulating guidelines. 
  
 “… they are starting in a very ad hoc way; they are not making preparations 
earlier on... They had not thought about the actual process that should be 
involved in formulating the guideline.” – P2 
 “…we as in Indian Academy of Paediatrics do this and RNTCP advises 
something else… This was not something that was very good for the children 
of the country….” PX 
 “…Department of Health Research is very aware of it but they did not actively 
participate... I think it reflects the silos in which we operate in this country...” PX 
“Because they were not told... Many of these sub-specialty streams were 
continuing to do whatever they were doing.”- P5 
“Currently we don’t have questions from the government and how the systematic 
reviews can be used….”- P3  
Mixed views on funding as a barrier to facilitate transition  
Mixed responses were elicited from participants about funding for guideline 
development and many participants did not even mention anything about funding. 
Participants noted that costs during guideline development were restricted to payments 
for transportation and accommodation of guideline developers and mentioned about 
the norm of not paying professional fees to panel members.  
 “I don’t think funds is an issue once we decide... Obviously it is not enough but 
usually we get funding from the professional societies. We obviously do not 
pay them to be our experts and that is not the usual system. We usually pay 
for stay and the travel but no professional fee is given. So that way you can say 
and that is well acceptable in the Indian context.”- P12 
 “.... we should develop capacity to develop guidelines and they should be funded 
by the government.” - P2 
 Although participants were not specifically asked about their opinions about the norm 
regarding payment of professional fees, none of the participants mentioned it to be a 
problem. On the contract, one participant, mentioned that:   
  
" … I spend a lot of time of my own and there was no monetary, no payment of 
any kind...it was a rare opportunity and we should do something and that 
motivated us and not money… For our own personal development and for our 
internal clarification... why not we also contribute something of that nature to 
science and for betterment of evidence.”- P9  
One participant noted that non-payment of professional fees affected timeliness of 
guideline development, while some others mentioned lack of dedicated time as a 
problem although they did not like it with the issue of fees.  
“... Not paying them anything and yet doing the work took some time.”- P14  
 “I think certainly for this there was a lack of dedicated time in which to do. I think 
people there were running around doing other things” – P13 
 
Inadequate methodological capacity to sustain transition   
 
Many participants recognised the need to build more capacity for evidence syntheses 
and regretted the lack of in-country capacity. Some participants felt that there was 
enough capacity available.   
“Such evidence based guideline development process is pretty much a full time 
job and as of now the number of people who are attuned to this kind of work is 
less. ....”- P 9  
 “…it would be better organised if much of the preparatory systematic reviews 
were done in-country.” - PX  
Theme 2: Guideline development is an academic activity restricted to elite 
institutions  
This theme looks at how guideline development is considered as an elite academic 
activity and its impact on the guideline development process.  
  
Academic elitism for selection of guideline panel members  
Many participants noted that that panel members were only from elite institutions and 
mainly from academic background but only a few recognised this as making guideline 
panels non-representative:  
 “There were so many people from the AIIMS, PGI and SGPGI(name of elite 
Indian institutions ) circles, very little beyond that - I think that part was missed 
in the guidelines.” – PX  
“.. they don’t necessarily have an ear to the ground. They are the specialists and 
not very community health oriented.” -P11 
 
One participant mentioned that problems during consultative process were caused by 
individuals who were included only due to their reputation: 
“… a few people had to be included because of their reputation and with very little 
interest in the science of extra pulmonary TB. Usually those were the types of 
people who created hurdles in smooth functioning of the process.” -PX 
Participants often justified the non-involvement of particular type of health 
professionals, state level representatives, or those implementing guidelines on the 
grounds of them not having published research or their perceived inability to 
comprehend guideline development process or lack of funds.  
“…certainly would include people who have published work … But to have people 
who have no grounding in the process of development of guidelines but they 
may be located in different parts of the country, but do not have anything to 
contribute to the process then I don’t think that would be very helpful in 
including them” - P2 
“… their (non-clinician health workers) role is mainly during their implementation 
of program but probably not so much in India in formulation of guidelines...”- 
P10  
  
 “… it could have been improved by the involvement of the persons involved in 
the primary health care from the start… Unfortunately, we did not have that 
much funds as well as infrastructure to take those workers on board…”- P15  
 
Elitism during consultative process for formulating recommendations  
Participants noted that elitism was observed in group processes wherein what was 
being said by panel members from elite institutions was expected to carry more weight 
than others and problems during the consultative process. 
 “I think it is more about professional ego. [ELITE INSITUTE] is a big centre it is 
very well established centre and they try to highlight the fact and that kind of 
made their points stronger...”- P10  
“…That was a main problem- tertiary care people making recommendations for 
district level care and maintaining their viewpoints despite others believing 
differently.”- P7 
Few participants noted that senior members from elite institutions played a key role to 
resolve disagreements. None of the participants mentioned of any structured system 
for resolving disagreements.  
 “…when there is a disagreement along a particular point then we go to a 
particular person, a particular senior person is there and they try to explain and 
then there is a lot of cross- discussion…”- P12  
 
Inadequate consideration on putting recommendations into practice  
The sub-theme discusses how the academic elitism in guideline development has 
meant that guidelines did not focus adequately on putting recommendations into 
practice and there is poor understanding among panel members about issues related 
to implementation.  
  
"… I was told ‘this(implementation) was not the primary focus of the guideline 
formulation’…. The guideline was more academic, its more literature search, 
weighing evidence, making sure that the bias was not there..."- P11  
“There are some people for whom implementation is a matter of choice, a matter 
of perspective and because this guideline group was a little heavy with 
academia and some of the recommendations tended to come from their 
personal positions - what they would do in our institutions. Not keeping in mind 
that guidelines were meant for the whole country where they might not have so 
much resource.”- P6 
Typically, facilitators and barriers to implementation were not discussed or described 
in cursory manner during consultative process and participants acknowledged that 
mechanism to evaluate whether guidelines have been actually being implemented was 
lacking:  
“In the end we make a comment about implementation of guidelines that we 
should ensure that these guidelines remain implemented. We should set up 
mechanism to see that these guidelines are finally implemented”- P1 
Participants mentioned costs, affordability and availability as factors what were 
detected were discussed.  
“to formulate the recommendations from the evidence and they looked at ratio of 
the benefit versus harm they looked at the other aspect of guidelines and you 
know the cost, availability and there was a good discussion.”- P 3 
One participant however mentioned that:   
“there was not a lot of consideration about costs... and it did not seem to be high 
on the agenda…”- P13 
Few participants perceived that differences in terms of state level or health care level 
diversity was not important for formulating recommendations and they said that:  
  
"… the diversity of the country will have more implications on implementation. 
The diversity of the country will not have any impact on the guideline 
recommendations. See TB would be same whether you are in desert or in hills 
or whether you are in sparsely populated or urbane population. "- P5 
“Regional and state level variation, uhh… there would not be variation about how 
to treat disease…The disease is the same all over India...”- P8  
 
Theme 3: Mixed views on patient involvement in guideline development  
All participants, except one, acknowledged that patients were not involved. Opinions 
however were mixed on the utility of involving patients for guideline development. While 
some participants regretted that the values and preferences of patients were ignored 
there were others who talked about difficulties in involving patients in guideline panels 
due to the lack of organised patient groups in India:  
“…they were definitely thinking about their own practice, which is fair enough, but 
I think they were not really keen to account for taking the patients perspectives 
of do they care about taking few more months of anti-tubercular drugs.” – P4  
 “Ideally, you know, patient groups and user groups and stuff but we don’t have 
any organised user groups as such... “-  P6 
There were some participants who expressed opinions that involvement of patients 
was not necessary in guideline panel and offered several explanations for it -  lack of 
education, poor knowledge about disease, and lack of training and non-involvement of 
patients being the norm in health sector. They usually tempered the response by a 
“don’t know “or “I am not sure”, but a few unequivocal responses were also elicited. 
“…Patients yes it would have to but at the moment.... I don’t know I really can’t 
answer that question. I am just looking about the kind of patients we deal with. 
We have a very population, some of them are(PAUSE), can be helpful.”- P1  
  
Many participants, some in spite of negative opinions about patient involvement, 
suggested various ways by which patient values and preferences might be taken into 
account. On the other hand, few participants mentioned that clinicians were well aware 
of the patient needs they are considered when formulating guidelines. 
 “..  people who are at interface like social worker they may perhaps contribute 
but directly patients in part of guideline! … I do not think patient participation 
will help  ...”- P9 
 “…the problem occurs with illiterate people who are poor, we call them to the 
meeting but we know what will be their view and they will tell that this drug is 
not affordable and is not available .. We feel that the group will take care of that 
but that is an issue and I am also not very sure if they should be included or 
not knowing their background but maybe somebody’s good intention could take 
care of those issues. " - P12 
Theme 4: Taboo & Poor understanding of conflict of interests 
The theme looks at the issues about taboo regarding industry-related conflict of 
interest(COI) and poor understanding of what COI entails and how it should be 
managed. 
Taboo around industry-related conflict of interest   
Most participants denied any COI in the guidelines in which they were involved on a 
few occasions vehemently. Some of them however mentioned that industry influence 
was common in ‘other guidelines’ which they knew about.  
“Certainly not, none at all, because for one thing there was nobody from the 
pharmaceutical company was involved... The other thing was none of the 
members who were members of the panel had any kind of stakes in these 
companies.”- P1.  
 “… it has happened sometimes occasionally in the past, particularly when newer 
vaccines. They are pushed a lot by the industry” – P5 
  
One participant, stated that panel members often did not disclose industry involvement 
but it was not a problem since other panel members were aware of it:   
“ No, No ,No, No. That we don’t allow…. It is strictly based on available scientific 
data … In India we have a people here you must be knowing that people are 
even indirectly they might be doing something but obviously in front nobody is 
going to tell that we are associated with this or this company. Although we know 
it but that factor never comes into play and we go strictly by merit, available 
literature and all that”- P12  
It is evident that involvement with industry or involving the industry in any guideline 
process is seen in a negative light and there is a taboo around involving industry-
related COI. This ‘taboo’ leads to compromises in the principle of transparency, forcing 
non-disclosure by guideline panel members as well as acceptance of this non-
disclosure by those managing COI.  
One participant, who was involved with the development of a government agency 
guideline, was suspect of the process being a “part of a larger agenda” and stated:  
“…I also got the nasty feeling that maybe some of this is controlled, that is just a 
speculation. For instance, why was GeneXpert being pushed down 
everybody’s throat… if you are talking about how everybody declared 
everything -  the conflict of interest disclosure was documented extremely well 
in the guideline formulation. If you are talking behind the scenes, one is not 
completely sure.” - PX 
This is probably reflective of the general lack of trust in procedures for managing COI 
handling procedures wherein non-disclosure of conflict of interest and industry 
influence is common.  
Poor understanding of issues related to conflict of interests  
Many participants mentioned that they had to face considerable difficulties in managing 
COI because people were reluctant to fill disclosure forms. They thought this was due 
to poor understanding about what COI actually is and people being unaccustomed to 
declare them:  
  
 “I don’t know, the conflicts of interests were signed and we got them completed 
as possible. It was relatively new to people to get them understand conflicts of 
interests…” – P13 
“I think it is just something that people were unaccustomed to having to do really”- 
P7  
Only senior level participants talked about academic COI and mentioned it as a cause 
of concern. One of them provided an example of how academic COI played a role 
during guideline development:  
 “.. some people do PCR(polymerase chain reaction) and then telling them that 
yes, that is an in-house test but we can’t have that particular test actually get 
into these guidelines because of the fact that at one place it has not enough 
evidence to validate it elsewhere... So you know we keep harping on about 
commercial conflict of interests but I think non-commercial conflicts of interests 
are strong and can be as harmful. That needs to be managed” – PX 
 
DISCUSSION  
A key strength of the study is its design, wherein guideline quality was appraised along 
with in-depth interviews of those involved in the development of the same guidelines. 
This enabled us to understand issues related to guideline development and its quality 
in a more comprehensive manner compared to other studies in which evaluated only 
guideline quality without trying to understand the interplay of several issues which 
affect guideline development.  
In our study we found that in general, for the included guidelines scores were low to 
moderate for the domains of ‘stakeholder involvement’, ‘rigour of development’, 
‘applicability’ and ‘editorial independence’ leading to poor overall quality in most cases.  
A  global systematic review of guideline quality had earlier found low scores in the 
domains of ‘stakeholder involvement’, ‘editorial independence’ and ‘applicability’ and 
moderate scores for the ‘rigour of development’ domain (32) .  However most of the 
  
guidelines included in that review was from high income countries and the results are 
now more than eight years old to enable any meaningful comparison. The results of 
our study, is in agreement with a 2015 study (33) on the quality of maternity 
management and family planning guidelines from India which found poor to moderate 
scores for domains similar to our study. 
The qualitative part of the study helps us understand the reasons behind the low to 
moderate scores for several quality parameters. We found that the key barriers towards 
transition to development of methodologically rigorous high quality guidelines are poor 
governance structures and inadequate in-country capacity for evidence search, 
syntheses and guideline methodology.  
Governance for guideline development is a major issue that needs to be addressed in 
the pluralistic health care system of India wherein health being a ‘State Subject’ is 
federated to the state. As such the GOI can only issue guideline and states can 
voluntary take up its implementation. As such the voluntary uptake of guideline 
implementation is often guided by political expediency. The question of “whether when 
health care is a State subject, is it desirable or useful to make a Central law”(10) has 
recently come into the policy discourse but is yet to be settled. However, the GOI might 
consider forming a centralised agency to coordinate and endorse guidelines developed 
by other health system actors as has been done in other countries with multiplicity of 
actors like Australia(34).  
A previous study on the growth of Cochrane in India  has found that systematic review 
authors (indicative of capacity) has been only  limited to elite institutes(35). As such 
the academic elitism noted in the study might be on account of the need to tap into 
whatever capacity is available in-country apart from attitudinal barriers wherein 
guideline development is seen as an academic activity. The INDEX TB guideline(28) 
which received high scores had engaged Cochrane consultants (from India and United 
Kingdom)for evidence search, appraisal and methodological advice. This might be 
indicative of ‘political will’, driven by contextual factors, to support the transition towards 
methodologically rigorous guidelines in spite of existing barriers but it also points 
towards the need for more in-country capacity and need for changes in the medical 
education system. 
Interestingly, participants expressed mixed views on funding as a barrier. This is on 
account of the norm of not paying any professional fees. For guidelines to become 
more evidence based in the future - systematic reviews will have to be commissioned, 
  
capacity development done and implementation issues considered more formally. To 
do all this a timely manner substantial funding would be required in the future.  
 
In the study we also found academic elitism at play during selection of panel members, 
and consultative processes for formulating recommendations. Those interviewed also 
expressed mixed views on inclusion of patient representatives. These attitudinal factor 
explains the poor scores in the ‘stakeholder involvement’ domain due to non-
involvement of health care professionals other than doctors, patient representatives as 
well as non-academic clinicians and clinicians from non-elite institutions. The heavy 
academic focus in guideline development also leads to inadequate consideration of 
putting recommendations into practice resulting in poor scores in the ‘applicability’ 
domain. .  
  
 
The lack of formal methods or use of majority voting for formulating recommendations 
is particularly problematic in the current scenario where the guideline panel 
composition and the consultative process is heavily biased in favour of the academia 
in elite institutions making it difficult for all voices to be heard or and ensure fair 
weightage to everyone’s argument (36) . The poor stakeholder involvement in guideline 
panel further amplifies the issue of elitism during the consultative process. As such 
change in guideline panel composition to include implementers and key stakeholders 
also needs to be accompanied by sensitisation of panel members about the issue of 
‘applicability’ or implementation of guidelines. The change in attitudes towards non-
clinician’s, patients and other stakeholders would need long term changes in the 
medical education curriculum. The issue of capacity of non-academic clinicians, other 
health professionals and patients might be realistic but there would always be panel 
members who would need to be familiarised with the processes and principles of 
appraising evidence and formulating recommendations. Instead of excluding such 
individuals or groups, provisions for training and supporting them to enable meaningful 
participation should be considered and the Government might consider affirmative 
action to ensure guideline developing agencies consider building their capacity and 
inclusion in guideline panels. Considering that attitudinal barriers would exist even if 
there panels are made inclusive there is a need to use more formal process for 
  
formulating recommendations like the Delphi method or nominal group technique to 
ensure adequate weightage of opinions to all stakeholders. 
 
The low scores on ‘editorial independence’ is due to taboo and misunderstandings 
surrounding COI which prevents transparency and discussion about it. Academic 
conflict of interests has been linked to authorship of original studies, grant funding and 
clinical revenue streams (example, from performing a diagnostic procedure like PCR 
as mentioned by a participant in this study) related to recommendations under 
consideration by the guideline panel(37, 38).In the wider context assessment of the 
potential influence of COI and their careful management when recommendations are 
being formulated  in recommendations can be assessed is essential to prevent loss of 
reputations of organisation developing guidelines(37). 
The recommendations for policy, practice and research based on the results of the study has 
been detailed in  
 
 
Table 5 . 
One limitation of the study is that only explored the views and perceptions of guideline 
developers and not of other groups involved in planning, implementing and using 
guidelines and are not involved in the guideline development process. Future 
qualitative studies need to include them. A key threat to the validity of the qualitative 
component of the study is social desirability bias or Hawthorne effect(39) which can be 
neutered through prior familiarization (40).  However, the application of this strategy 
was beyond the scope of this study although few participants were known to one 
author(SB) previously on a professional basis. Participant checking was during the 
course of interviews but no respondent validation(41) was attempted. 
During the course of analyses, adequate attention was given  to  deviant cases wherein 
the data did not support or appeared to contradict themes emerging from the rest of 
the data to improve the credibility of the research(42). Another important factor that 
was considered during the analyses was the phenomenon of ‘mutedness’. Mutedness 
is the phenomenon wherein the less powerful tends to internalize norms which are 
supported by more powerful groups (43). This was particularly relevant to the theme of 
guidelines process being an academic activity restricted to elite institutions and was 
  
observed wherein non-elite and non-academic participants often did not see it is a 
problem or offered explanations for such an event.  
CONCLUSION   
Progress towards better quality guidelines which are developed in a transparent, 
evidence based and a systematic manner in India would require governance, 
planning and dedicated funding supported by changes in the medical curriculum and 
capacity building efforts. Issuing agencies need to adopt policies to make panels 
more representative, search and appraise evidence appropriately, have formal 
process for formulating recommendations and disclose conflict of interests.  
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(narrow, i.e. only 
screening, diagnosis 
and/or treatment; 








Profit Organisation / 
Pharmaceutical) 
  ISCHAEMIC HEART DISEASE (IHD) 
Banerjee and 
Kumar, 2011 
Guideline New Unclear Multiple Broad 2 Not mentioned 
Bhandari et al., 
2012 
Guideline New Professional 
Society 
Multiple Broad 19 Not mentioned 














New Unclear Tertiary Narrow (diagnosis and 
treatment) 
5 Not mentioned 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
Gupta et.al, 2013 Guideline New Professional 
Society 
Multiple Broad 56 Non-Profit Organisation 
LOWER RESPIRATORY INFECTIONS (LRI) 
Dheeraj et al., 
2012 
Guideline New Professional 
Society 
Multiple Broad 52 Non-Profit Organisation 
TUBERCULOSIS (TB) 








Guideline Update Government 
Agency 
Multiple Broad Not Clear Not mentioned 
CTBD-MoHFW 
2012 
Guideline New Government 
Agency 
Multiple Broad Not Clear Not mentioned 
Ashok et al., 
2012 
Guideline Update Government 
Agency 






Guideline New Government 
Agency 

































































































































(Guideline recommended for use?) 
ISCHEMIC HEART DISEASE 
Banerjee and 
Kumar, 2011 
67% 35% 16% 74% 22% 11% 28% Reviewer 1: No 
Reviewer 2: No 
Reviewer 3:  Yes with modifications 
Bhandari et al., 
2012 
69% 52% 65% 65%% 29% 33% 72% Reviewer 1: Yes, with modifications 
Reviewer 2: Yes, with modifications   
Reviewer 3: Yes 
Dalal et.al, 
2014  
76% 48% 25% 74% 32% 33% 50% Reviewer 1: Yes, with modifications 
Reviewer 2: Yes, with modifications 




87% 41% 60% 89% 54% 11% 67% Reviewer 1: Yes, with modifications 
Reviewer 2: Yes  
Reviewer 3: Yes 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Gupta et.al, 
2013 
81% 52% 58% 91% 32% 44% 72% Reviewer 1: Yes, with modifications 
Reviewer 2: Yes  
Reviewer 3: Yes 
LOWER RESPIRATORY INFECTIONS 
Dheeraj et al., 
2012 
81% 57% 63% 91% 40% 61% 78% Reviewer 1: Yes, with modifications 
Reviewer 2: Yes, with modifications   
Reviewer 3: Yes 
TUBERCULOSIS 
IAP, 2010 85% 33% 30% 80% 51% 69% 56% Reviewer 1: No 
Reviewer 2: Yes, with modifications 
Reviewer 3: Yes, with modifications  
CTBD-MoHFW 
2010  
91% 48% 31% 76% 65% 11% 72% Reviewer 1: Yes, with modifications 
Reviewer 2: Yes, with modifications 




63% 26% 24% 59% 67% 25% 39% Reviewer 1: No 
Reviewer 2: Yes, with modifications 
Reviewer 3: Yes, with modifications 
Ashok et al., 
2012 
57% 39% 15% 59% 24% 56% 22% Reviewer 1: No 
Reviewer 2: No 
Reviewer 3: No 
CTBD-MoHFW 
2016 
98 % 78% 94% 94% 75% 92% 94% Reviewer 1: Yes 
Reviewer 2: Yes 
Reviewer 3: Yes 
  
Table 3 : Characteristics of participants interviewed 
Participant Characteristic Details 
Gender  Male -  10 
Female -5 
Seniority Level  
 
Junior -  3 
Middle -4 
Senior -8 
Background Non- Clinician- 1 
Clinician, Generalist- 2 
Clinician- Specialist- 10 
Clinician, Others-  2 
Health Sector   
 
Government – 7  
Non-Profit – 7  
Private- 1 
Prior experience in conducting systematic Review Yes - 6 
No - 9 




Table 4 :  Main Themes & Sub-Themes for the study  




















on funding as 










Theme 2: Guideline development is an academic activity restricted to elite 
institutions 
Sub-Theme:  
Academic elitism for 












Theme 3: Mixed views on patient involvement in guideline development 
Theme 4: Taboo & Misunderstanding surrounding conflict of interests 
Sub-Theme: 
 Taboo around industry-related conflict of 
interest   
Sub-Theme:  
Poor understanding of issues related to 




Table 5 :  Recommendations for Policy and Practice 
1. Development of governance structures, a planned approach towards 
guideline development, and dedicated funding for capacity building, 
commissioning of systematic reviews and payment of professional fees are 
key issues which need attention from guideline developing organisations. 
These are essential to ensure accountability, timeliness and methodological 
rigour in guideline development. 
2. There is a need for governance for guideline development and considering 
the federal nature of Indian health polity and the dominant role of the private 
sector in India formation of a centralised agency to coordinate and 
endorse guidelines developed by other health system actors might be 
considered. Such an agency, if set within the ambit of an appropriate 
  
legislative framework can ensure that guidelines meet minimum standards of 
quality 
3. Multidisciplinary guideline panels, with adequate inter-disciplinary balance 
and involvement of relevant stakeholders ensures ‘ownership’ and support 
for implementation and leads to formulation of more relevant 
recommendations (37, 44). Guideline developing organisations and the GOI 
should consider changing policies or adopting legislation to ensure adequate 
representation in guideline panels for:  
 all categories of health professionals including those who are not 
clinicians (nurses, pharmacists, community health workers, 
physiotherapists, public health managers, policy makers etc.) from all 
levels of health care and from all sectors 
 non-academic clinicians and clinicians from non-elite 
institutions  
 individuals with technical skills for information retrieval, evidence 
syntheses, health economics, project management and editing. 
 patient representatives  
There would always be panel members who would need to be familiarised 
with the processes and principles of appraising evidence and formulating 
recommendations. Instead of excluding such individuals or groups, 
provisions for training and supporting them to enable meaningful 
participation should be considered. 
4. Considering the negative perceptions and difficulties in involving patients in 
guideline panels using other approaches to incorporate patient values 
and preferences such as indirect input in the form of written testimonials or 
video tapes, and public consultation before finalisation of guidelines (45) 
might be considered as an interim measure.  
5. In order to ensure fair weightage of opinions of all stakeholders it is essential 
to:   
 Use a formal process for formulating recommendations 
like the Delphi method or nominal group technique (46) 
Voting as a method is inappropriate in the current context 
where elite academic institutions are in majority. 
 Having group leaders or moderators who are acceptable 
by all stakeholders and is adept at managing group 
  
processes rather than the most senior person or from an elite 
institution.  
 
6. Disclosure of financial and academic COI should be a prerequisite to 
guideline panel membership before the process starts and this should be 
strictly enforced. Non-disclosure when known should be dealt with 
appropriately. 
 
7. Long term transition and acceptability of transparent, evidence based 
approaches and multidisciplinary panels for guideline development might 
need support through changes in medical curriculum at the undergraduate 
and post-graduation level to include concepts of evidence based medicine, 
conflict of interest and patient centred care. This will ensure better 
understanding and changes in attitudes and over time decrease the need for 





Figure 1 : PRISMA Flow Diagram showing selection of guidelines included in the study 
  
 
Figure 2: Box & Whisker Plot showing AGREE II domain scores of Indian guidelines on IHD, LRI, 
COPD, TB 
